گزینه های مناسب بیومارکر ریبونوکلئیک اسید برای تشخیص اولیه سرطان
ترجمه نشده

گزینه های مناسب بیومارکر ریبونوکلئیک اسید برای تشخیص اولیه سرطان

عنوان فارسی مقاله: گزینه های مناسب بیومارکر ریبونوکلئیک اسید برای تشخیص گروهی در مرحله اولیه سرطانهای شایع
عنوان انگلیسی مقاله: Ribonucleic-acid-biomarker candidates for early-phase group detection of common cancers
مجله/کنفرانس: ژنومیکس - Genomics
رشته های تحصیلی مرتبط: پزشکی، زیست شناسی
گرایش های تحصیلی مرتبط: پزشکی مولکولی، علوم سلولی و مولکولی، ژنتیک، ایمنی شناسی
کلمات کلیدی فارسی: غربالگري سرطانها، نشانگرهاي زيستي رایج، بهم ریختگی miRNA، تشخيص غير تهاجمی
کلمات کلیدی انگلیسی: Cancers screening، Circulating biomarkers، miRNA dysregulation، Non-invasive diagnosis
نوع نگارش مقاله: مقاله مروری (Review Article)
نمایه: Scopus - Master Journals List - JCR - MedLine
شناسه دیجیتال (DOI): https://doi.org/10.1016/j.ygeno.2018.08.011
دانشگاه: Protein Research Center, Shahid Beheshti University, G.C., Tehran, Iran
ناشر: الزویر - Elsevier
نوع ارائه مقاله: ژورنال
نوع مقاله: ISI
سال انتشار مقاله: 2020
ایمپکت فاکتور: 3/000 در سال 2019
شاخص H_index: 135 در سال 2020
شاخص SJR: 1/308 در سال 2019
شناسه ISSN: 0888-7543
شاخص Quartile (چارک): Q2 در سال 2019
فرمت مقاله انگلیسی: PDF
تعداد صفحات مقاله انگلیسی: 6
وضعیت ترجمه: ترجمه نشده است
قیمت مقاله انگلیسی: رایگان
آیا این مقاله بیس است: خیر
آیا این مقاله مدل مفهومی دارد: ندارد
آیا این مقاله پرسشنامه دارد: ندارد
آیا این مقاله متغیر دارد: ندارد
کد محصول: E14430
رفرنس: دارای رفرنس در داخل متن و انتهای مقاله
فهرست انگلیسی مطالب

Abstract


1- Introduction


2- Common lethal cancers


3- Investigating miRNA profiling in cancers


4- MiR candidates for early phase group detection


5- Conclusion


References

نمونه متن انگلیسی مقاله

Abstract


Cancer is considered as a challenging lethal agent around the world and its detection at early stages would help prevention of the high mortality. Among the widely used biomarkers in clinical diagnosis of cancer, extracellular non-coding RNAs as ribonucleic acid biomarkers serve as state-of-the-art candidates for molecular diagnosis. In that regard, microRNAs are of great priority mainly because of high variety and stability in body fluids. Accordingly, common miRNAs among most prevalent cancers could help us (pre)diagnose cancer with high accuracy in target samples. In this study, common lethal cancers to humans were investigated in case of miRNA profiles to determine the possible common correlation between miRNA up-regulation or down-regulation (as a ribonucleic acid biomarker) and developing the cancers. It was shown that among the investigated miRNAs, five typical extracellular miRNAs (miR-18a, miR-21, miR-155, miR-221, and miR-375) dysregulation are predominant in most cancer varieties comprising breast, colon, lung, prostate, pancreas, gastric, ovarian, esophagus and liver. This could serve as an appropriate target site for developing point-of-care approaches for cancer detection e.g. designing diagnostic biosensor-based microarrays or kits for both quantification and qualification of the biomarkers. Besides, the miRNA candidates could be efficiently applied to cancer therapeutic approaches.


Introduction


Cancer keeps on being a remarkable cause of worldwide mortality in spite of many years of effort and cost. Deadliest types of cancers to human includes pancreas, liver, lung and bronchus, prostate/breast, colon, rectum and ovary [1–3]. Most of cancers do not induce clinical symptoms until in the later stages when the therapeutic treatment is no longer an option. However, detection of cancer at first stages, regardless of its origin, greatly increases the chance of effective treatments. In spite of much research in cancer biomarkers, only a few are considered for early diagnosis of common cancers. In addition, there is not a general biomarker for population screening in order to detect both asymptomatic cancers and early-staged cancers. Hence, investigating more sensitive and non-invasive biomarkers is still a promising challenge in cancer diagnosis and prognosis [4]. Accessing circulating cancer biomarkers through biological fluids using liquid biopsy seems to propose a promising cost-effective and non-invasive solution. Literally, cf-miRNAs are considered as ideal circulating cancer biomarkers due to their ease of access and quantification, besides integration with other macromolecules e.g. proteins, and high stability in plasma [5, 6]. MiRNAs are endogenous, small (18–24 nt), non-coding (nc) RNA molecules that play important regulatory roles in cell proliferation, apoptosis, metastasis and angiogenesis [7]. Dysregulated miRNA(s) have both oncogenic and tumor-suppressing effects depending on their corresponding targets. The increase or decrease of miRNAs is related to the role of their target genes in cancer progression or regression. MiRNAs are mainly categorized in two groups: 1) OncomiRs that are up-regulated in cancers to target protein-coding transcripts in tumor suppressive pathways, and consequently increase cell proliferation, invasion and metastasis. 2) Tumor-suppressor miRNAs that repress the oncogenic genes and their down-regulation in cancer increases the oncogenic activity [8]. MiRNAs show various expression patterns in tissue and blood of many cancers in comparison with normal samples. Furthermore, miRNA profiles in cancers with various tissue origins are distinct from each other [9].

  • اشتراک گذاری در

دیدگاه خود را بنویسید:

تاکنون دیدگاهی برای این نوشته ارسال نشده است

گزینه های مناسب بیومارکر ریبونوکلئیک اسید برای تشخیص اولیه سرطان
نوشته های مرتبط
مقالات جدید
نماد اعتماد الکترونیکی
پیوندها